EGFR and toxicity: New biological drugs have been developed, such as monoclonal antibodies against epidermal growth factor receptor (EGFR) (cetuximab or panitumumab) or vascular endothelial growth factor (VEGF) (bevacizumab or ramucirumab), which also showed serious limitations both related to specific side effects (i.e., diarrhea, ocular-skin toxicity, etc) and their low efficacy in some types of CC [3,4].